CoChat
Sign Up
Cited by 52

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Predictors of Atherosclerosis

Homma, Yasuhiko·2004·Journal of Atherosclerosis and Thrombosis
DOI 10.5551/jat.11.265
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.5551/jat.11.265

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Increased hepatic LDLR expression is strongly associated with a decreased risk of developing cardiovascular disease in humans.

    “which is strongly associated with a decreased risk of developing cardiovascular disease in humans”

    From A novel posttranscriptional mechanism for dietary cholesterol-mediated suppression of liver LDL receptor expression (2014) · cites this paper as [5]

    The Plasma Lipoproteins section says that elevated plasma LDL is a risk factor for coronary artery disease and recommends reducing LDL cholesterol in certain high-risk subjects. It does not address hepatic LDL receptor (LDLR) expression or an association between increased expression and reduced cardiovascular disease risk in humans (searched: hepatic LDL receptor expression; LDL receptor liver expression). (LLM, conf=0.76)

    Experimental — accuracy not yet measured

  • Increased hepatic LDLR expression results in improved clearance of plasma LDL-C through receptor-mediated endocytosis.

    “Increased hepatic LDLR expression results in improved clearance of plasma LDL-C through receptor-mediated endocytosis”

    From A novel posttranscriptional mechanism for dietary cholesterol-mediated suppression of liver LDL receptor expression (2014) · cites this paper as [5]

    The Plasma Lipoproteins section discusses LDL-C as a clinical measure and LDL levels as a coronary risk factor, but does not address hepatic LDLR expression or LDL clearance. Searches for LDL receptor, receptor-mediated endocytosis, and clearance found no passage establishing the claimed mechanism. (LLM, conf=0.76)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 52

  1. (1) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA, 285: 2486−2497, 2001 · DOI · Paper page
  2. (2) Anderson KM, Wilson PWF, Odell PM, and Kannel WB: An update coronary risk profile. A statement for health professionals. Circulation, 83: 356−362, 1991 · DOI · Paper page
  3. (3) Wilson PWF, D’Agostino RB, Revy D, Belanger AM, Silbershatz H, and Kannel W: Prediction of coronary heart disease using risk factor categories. Circulation, 97: 1837−1847, 1998 · DOI · Paper page
  4. (4) D’Agostino RB, Grandy S, Sullivan LM, and Wilson P, for the CHD Risk Prediction Group: Validation of the Framingham coronary heart disease prediction scores. Results of a Multiple Ethinic Groups Investigation. JAMA, 286: 180−187, 2001 · DOI · Paper page
  5. (5) Brindle P, Emberson J, Lampe F, Walker M, Wincup P, Fahey T, and Ebrahim S: Predictive accuracy of the Framingham coronary risk score in British men: prospective cohot study. BMJ, 327: 1267−1274, 2003 · DOI
  6. (6) Havel RJ and Kane JP: Introduction: metabolism and chemical composition of plasma lipoproteins. In: The Metabolic and Molecular Bases of Inherited Diseases. 8th Ed, ed by Sciver CR, Beauded AL, Sly WS, Valle D, Childs B, Kinzler KW, and Vogelstein B, pp 2705−2716, McGraw-Hill, New York, 2001
  7. (8) Waadius G, Jungner I, Holme I, Aastveit AH, Kolar W, and Steiner E: High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet, 358: 2026−2033, 2001 · DOI
  8. (9) Williams K, Sniderman AD, Sattar N, D’Agostini R, Wagenknecht LE, and Haffner SM: Comparison of apolipoprotein B and low-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study (IRAS). Circulation, 108: 2312−2316, 2003 · DOI
  9. (10) Sniderman AD, Furberg CD, Keech A, van Lennep JER, Frolich J, Junger I, and Walldius G: Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet, 361: 777−780, 2003 · DOI
  10. (11) The BIP Study Group: Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention Study. Circulation, 102: 21−27, 2000 · DOI · Paper page
  11. (12) Sacks FM, Alaupovic P, Moye LA, Cole TG, Sussex B, Stampfer MJ, Pfeffer MA, and Braunwald E: VLDL, apolipoproteins B, CIII, and E, and risk of recurrent events (CARE) trial. Circulation, 102: 1886−1892, 2000 · DOI · Paper page
  12. (13) Robins JR, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, MacNamara JR, Kashap ML, Hershman JM, Wexler LF, and Rubins HB, for VA-HIT Study Group: Relation of gemfibrozil treatment and lipid levels with major coronary events. JAMA, 285: 1585−1591, 2001 · DOI
  13. (14) Sharrett AR, Chambless LE, Heis G, Paton C, and Patsch W: Association of postprandial triglyceride and retinyl palmitate responses with asymptomatic carotid artery atherosclerosis in middle-aged men and wemen. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol, 15: 2122−2129,1995 · DOI
  14. (16) Talmud PJ, Hawe E, Miller GJ, and Humphries SE: Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men. Arterioscler Thromb Vasc Biol, 22: 1918−1924, 2002 · DOI
  15. (17) McNamara JR, Shah PK, Nakajima K, Cupples LA, Wilson PWF, Ordovas JM, and Schaefer EJ: Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study, Atherosclerosis, 154: 229−236, 2001 · DOI
  16. (18) Yamaguchi H, Homma Y, and Handa S: Biochemical markers of vasospastic coronary artery disease. Nutr Metab Cardiovasc Dis, 13: 365−371, 2003 · DOI
  17. (19) Skoglund-Andersson C, Gene Bond RTM, de Faire U, and Hamsten: LDL particle size distribution is associated with intima-media thickness in 50-year-old men. Arterioscler Thromb Vasc Biol, 19: 2422−2430, 1999 · DOI
  18. (20) Otvos JD, Shalaurova I, Freedman DS, and Rosenson RS: Effects of pravastatin treatment on lipoprotein subclass and particle size in the PLAC-I trial. Atherosclerosis, 160: 41−48, 2002 · DOI
  19. (21) The Diabetes Atherosclerosis Intervention Study (DAIS): Relationship between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease. Circulation, 107: 1733−1737, 2003 · DOI
  20. (22) Homma Y, Moriguchi EH, Sakane H, Ozawa H, Nakamure H, and Goto Y: Effects of probucol on plasma lipoprotein subfractions and activity of lipoprotein lipase and hepatic triglyceride lipase. Atherosclerosis, 88: 175−181,1991 · DOI
  21. (23) Sniderman AD: How, when, why to use apolipoprotein B in clinical practice. Am J Cardiol, 90: 48i−54i, 2002 · DOI
  22. (24) Maruyama C, Imamura K, and Teramoto T: Assessment of LDL particle size by triglyceride/HDL-cholesterol ratio in non-diabetic, healthy subjects without prominent hyperlipidemia. J Atheroscler Thromb, 10: 186−191, 2003 · DOI
  23. (25) de Graaf J, Hak-Lemmers HL, Hectors MP, Demacker PN, Hendriks JC, and Stalenhoef AF: Enhanced susceptibility to in vitro oxidation of dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb, 11: 298−306, 1991 · DOI
  24. (26) Tribble DL, Holl LG, Wood PD, and Krauss RM: Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis, 93: 189−199,1992 · DOI
  25. (28) Lusis AL: Atherosclerosis. Nature, 407: 233−241, 2000 · DOI
  26. (29) Lehtimaki T, Lehtinen S, Solaviki T, Nikkila M, Jaakkola O, Joleka H, Yla-Herttuala S, Luoma JS, Koivula T, and Nikkari T: Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. Arterioscler Thromb Vasc Biol, 19: 23−27, 1999 · DOI
  27. (30) Yasunobu Y, Hayashi K, Shingu T, Yamagata T, Kajiyama G, and Kambe M: Coronary atherosclerosis and oxidative stress as reflected by autoantibodes against oxidized low-density lipoprotein and oxysterols. Atherosclerosis, 155: 445−453, 2001 · DOI
  28. (31) Holvoet P, Mertens A, Verhamme P, Bogaerts K, Beyens G, Verhaeghe R, Collin D, Muls E, and Van de Werf FV: Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol, 21: 844−848, 2001 · DOI
  29. (32) Vasankari T, Ahotupa M, Toikka J, Mikkola J, Irjara K, Pasanen P, Neuvonen K, Raitakari O, and Vikari J: Oxidized LDL and thickness of carotid intima-media are associated with coronary atherosclerosis in middle-aged men: lower levels of oxidized LDL with statin therapy. Atherosclerosis, 155: 403−412, 2001 · DOI
  30. (33) Holvoet P, Harris TB, Tracy RP, Verhamme P, Newman AB, Rubin SM, Simonsick EM, Colbert LH, and Kritchevsky SB: Association of high coronary heart disease risk status with circulating oxidized LDL in the well-functioning elderly. Findings from the health, aging, and body composition study. Arterioscler Thromb Vasc Biol, 23: 1444−1448, 2003 · DOI
  31. (34) Rossi GP, Cesari M, De Toni R, Zanchetta M, Maiolino G, Pedon L, Ganzaroli C, Maiolino P, and Pessina AC: Antibodies against oxidized low-density lipoproteins and angiographically assessed coronary artery disease in white patients. Circulation, 108: 2467−2472, 2003 · DOI
  32. (35) Homma Y, Homma K, Iizuka S, and Iigaya K: Effects of fluvastatin on plasma levels of low-density lipoprotein subfractions, oxidized low-density lipoprotein, and soluble adhesion molecules: a twenty-four-week, open-label, dose-increasing study. Curr Therapeutic Res, 64: 236−247,2003 · DOI
  33. (36) Maher VMG, Brown BG, Marcovina SM, Hillger LA, Zhao X-Q, and Albers JJ: Effect of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA, 274: 1771−1774, 1995 · DOI
  34. (37) Von Eckardstein A, Schulte H, Cullen P, and Assmann G: Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. J Am Coll Cardiol, 37: 434−439, 2001 · DOI
  35. (38) Luc GL, Bard J-M, Arveler D, Ferrieres J, Evans A, Amouyel P, Fruchard J-C, and Ducimetiere P, on behalf of the PRIME Study Group: Lipoprotein(a) as a predictor of coronary heart disease: the PRIME Study. Atherosclerosis, 163: 377−384, 2002 · DOI
  36. (40) Girman CJ, Rhodes T, Mercouri M, Pyorala K, Kjekshus J, Pedersen TR, Beere PA, Gotto AM, Clearfield M; 4S Group, and the AFCAPS/TexCAPS Research Group: The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol, 93: 136−141, 2004 · DOI
  37. (41) Ninomiya JK, L’Italien G, Criqui MH, Whyte JL, Gamst A, and Chen RS: Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation, 109: 42−46, 2004 · DOI
  38. (42) Marroquin OC, Kip KE, Kelley DE, Johnson BD, Shaw LJ, Merz CNB, Sharaf BL, Pepine CJ, Sopko G, and Reis SE, for the Women’s Ischemia Syndrome Evaluation Investigators: Metabolic syndrome modifies the cardiovascular risk associated with angiographic coronary artery disease in women. A report from the Women’s Ischemia Syndrome Evaluation. Circulation, 109: 714−721, 2004 · DOI · Paper page
  39. (43) Solymoss BC, Bourassa MG, Campeau L, Sniderman A, Marcil M, Lesperance S, and Varga S: Effect of increasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease angiographic severity. Am J Cardiol, 93: 159−164, 2004 · DOI
  40. (44) Ross R: Atherosclerosis — an inflammatory disease. N Engl J Med, 340: 115−126, 1999 · DOI · Paper page
  41. (45) Ridker PM, Hennekens CH, Buring JE, and Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med, 342: 836−843, 2000 · DOI · Paper page
  42. (46) Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon III RO, Criqui M, Fald YY, Fortman SP, Hong Y, Myers GL, Rifai N, Smith SC, Taubart K, Tracy RP, and Vinicor F: Markers of inflammation and cardiovascular disease. Application to clinical and public health plactice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation, 107: 499−511, 2003 · DOI · Paper page
  43. (47) Ridkar PM, Buring JE, Cook NR, and Rifai N: C-reactive protein, metabolic syndrome, and risk of incident cardiovascular events. An 8 year follow-up of 14 719 initially healthy American women. Circulation, 107: 391−397, 2003 · DOI · Paper page
  44. (48) Kalvegren H, Majeed M, and Bengtsson T: Chlamydia pneumoniae binds to platelets and triggers p-selectin expression and aggregation. Arterioscler Thromb Vasc Biol, 23: 1677−1683, 2003 · DOI
  45. (49) Pietroiusti A, Diomedi M, Silverstrini M, Cupini LM, Gomez-Miguel MJ, Bergamashi A, Magrini A, Carrabs T, Vellini A, and Galante A: Cytotoxin-associated gene-A-positive helicobactor pylori strains are associated with atherosclerotic stroke. Circulation, 108: 580−584,2002 · DOI
  46. (50) Grahame-Clark C, Chan NN, Andrew D, Ridgway GL, Betteridge DJ, Emery V, Colhoun HM, and Vallance P: Human cytomegalovirus seropositivity is associated with impaired vascular function. Circulation, 108: 678−683,2003 · DOI
  47. (51) Schini-Kerth VB: Homocysteine, a proinflammatory and proatherosclerotic factor. Role of intracellular reactive oxigen species. Circulation Res, 93: 271−273, 2003 · DOI
  48. (52) Zylberstein DE, Bengtsson C, Bjorkelund C, Landaas S, Sundh V, Thelle D, and Lissner L: Serum homocysteine in relation to mortality and morbidity from coronary heart disease. A 24-year follow-up of the population study of women in Gothenburg. Circulation, 109: 601−606, 2004 · DOI
  49. (53) Sobel BE, Taatjes DJ, and Schneider DJ: Intramural plasminogen activator inhibitor type-1 and coronary atherosclerosis. Arterioscler Thromb Vasc Biol, 23: 1979−1989, 2003 · DOI
  50. (55) Zhou R-H, Shi Q, Gao H-Q, Shen B-J: Changes in serum interleukin-8 and interleukin-12 levels in patients with ischemic heart disease in a Chinese population. J Atheroscler Thromb, 8: 30−32,2001 · DOI
  51. (56) Cesari M, Penninx BWJH, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, Rubin SM, Ding J, Simonsick EM, Harris TB, and Pahor M: Inflammatory markers and onset of cardiovascular events. Results from the Health ABC Study. Circulation, 108: 2317−2322, 2003 · DOI · Paper page
  52. (57) Kumada M, Kihara S, Somitsuji S, Kawamoto T, Matsumoto S, Ouchi N, Arita Y, Okamoto Y, Shimomura I, Hiraoka H, Nakamura T, Funahashi T, and Matsuzawa Y for Osaka CAD Study Group: Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol, 23: 85−89, 2003 · DOI

Cited by

Sorted by citations

Metadata

Authors
Homma, Y.
Affiliations
Health Evaluation and Promotion Center, Tokai University Hospital
Venue
Journal of Atherosclerosis and Thrombosis
Publisher
Japan Atherosclerosis Society
Published
2004
Volume
11
Issue
5
Pages
265-270
ISSN
  • 1340-3478
  • 1880-3873
DOI
10.5551/jat.11.265
Cited by
52
References
4
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review